Table 2. Covariates and corresponding coefficients of the survival models and logistic regression model.

	Time to event 1 (first 12 months)	Time to event 1 (> 12 months)	Type of event 1*	Time to event 2
Model type	Loglogistic	Exponential	Logistic	Weibull
Covariate	Coefficient (s.e.)	Coefficient (s.e.)	Coefficient (s.e.)	Coefficient (s.e.)
Constant	1.060 (0.393)	5.227 (0.663)	-1.778 (0.790)	2.804 (0.249)
Age (yr)	0.012 (0.005)	-0.027 (0.009)	0.037 (0.013)
Sex (male vs. female)				-0.382 (0.185)
Histology (non-clear cell vs. clear cell)	-0.229 (0.112)
Prior nephrectomy (yes vs. no)	0.783 (0.130)
Number of metastatic sites (more than 1 vs. 1)	-0.306 (0.120)			-0.387 (0.199)
WHO performance status (2–4 vs. 0–1)	-0.585 (0.136)
Liver metastases (yes vs. no)	-0.459 (0.137)			0.632 (0.164)
Bone metastases (yes vs. no)	0.277 (0.113)	-0.330 (0.170)		-0.421 (0.150)
Brain metastases (yes vs. no)				-0.657 (0.238)
Thrombocytes (>ULN vs. normal)			0.587 (0.320)	-0.360 (0.183)
Neutrophil count (>ULN vs. normal)	-0.258 (0.136)
Albumin (<LLN vs. normal)	-0.290 (0.137)		1.074 (0.381)	-0.388 (0.196)
Alkaline phosphatase (>ULN vs. normal)	-0.269 (0.129)
First-line sunitinib (vs. no targeted therapy)	0.915 (0.124)	-0.602 (0.201)
First-line temsirolimus (vs. no targeted therapy)	0.580 (0.244)	-1.529 (0.611)
First-line other (vs. no targeted therapy)	0.992 (0.273)	0.339 (0.375)
Second-line everolimus (vs. sorafenib)				-0.143 (0.191)
Second-line other (vs. sorafenib)				-0.388 (0.181)
TTE 1 (TTE 1 > 12 months vs. TTE 1 < = 12 months)			-0.641 (0.270)	0.537 (0.147)
Shape parameter	0.669 (0.028)			1.625 (0.137)

NOTE. Lung metastases, heamaglobin, corrected serum calcium and lactate dehydrogenase were considered for inclusion in the survival models and logistic regression model, but excluded through backward and/or forward selection.

Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal; TTE, time to event.

*0 = second-line therapy/ 1 = death.